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Summary
 Background Despite aggressive treatment with radiotherapy, which is often combined with 
chemotherapy, local persistence occurs in 18–40% of patients with nasopharyn-
geal carcinoma. Brachytherapy is one of the methods for the re-treatment of pa-
tients with locally recurrent nasopharyngeal carcinoma.
 Aim The aim of this paper was to evaluate the effectiveness of HDR (high-dose-rate) 
treatment of patients with locally recurrent nasopharyngeal carcinoma.
 Materials/Methods The study took the form of a retrospective analysis and included a group of 28 
patients treated in the Brachytherapy Department of the Oncology Centre in 
Bydgoszcz during the years 1995–2000. Brachytherapy was carried out using 
a Rotterdam applicator and the MicroSelectron HDR apparatus produced by 
Nucletron. Irradiation was based on doses of 36 Gy, i.e. 6 Gy applied once a week, 
and 51 Gy i.e. 3 Gy applied twice a week. This paper presents recovery probabili-
ty, overall survival and recurrence-free survival within the analysed group of pa-
tients.
 Results The results obtained prove intracavitary HDR (high-dose-rate) brachytherapy to 
be a viable method for the treatment of patients with recurring nasopharyngeal 
carcinoma.
 Conclusions The higher the total dose applied by means of brachytherapy, the greater the 
chance of locally successful treatment, moreover, the time that elapses before re-
currence is considered to be an important factor infl uencing recurrence-free sur-
vival time.
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BACKGROUND
Teleradiotherapy is a standard method for the 
treatment of patients with nasopharyngeal car-
cinoma. Unfortunately, despite aggressive irradi-
ation, which is often combined with chemother-
apy, local recurrence remains a major source of 
treatment failures, occurring in 18-40% of pa-
tients. Recurrence is classifi ed as the develop-
ment of a local tumour, usually occurring with-
in a period of up to two years from completion 
of treatment [1–3].
Treatment of patients with recurrent nasopharyn-
geal carcinoma is a major challenge. Therapy in-
cludes numerous treatment options such as sur-
gery, stereotactic radiosurgery, conventional 
radiotherapy, IMRT and brachytherapy [4–10]. 
Re-irradiating patients with recurrent nasopha-
ryngeal carcinoma allows attainment of 25–52% 
rates of 3-year overall survival [6,11]. Achieving a 
complete recovery however, often results in post-
irradiation complications. Therefore, reducing 
the irradiation of healthy tissues is absolutely vi-
tal and it is brachytherapy that provides us with 
an opportunity to do so. Use of this therapy facil-
itates the application of a high dose of radiation 
within a tumour while reducing it dramatically 
outside the treated fi eld. Brachytherapy may be 
used either as an independent method of treat-
ment or in association with external irradiation 
[4,5] for carefully selected groups of patients with 
local recurrent carcinoma, treated with radical 
teleradiotherapy.
AIM
The aim of this paper was to evaluate the effec-
tiveness of HDR (high-dose-rate) treatment of 
patients with locally recurrent nasopharyngeal 
carcinoma.
MATERIALS AND METHODS
A retrospective analysis of a group of 28 patients 
with recurring nasopharyngeal carcinoma was car-
ried out. The patients were treated between 1995 
and 2000 in the Brachytherapy Department of the 
Oncology Centre in Bydgoszcz. Detailed charac-
teristics of the patients are shown in Table 1. Local 
recurrence was defi ned as the presence of a tu-
mour shoot 6 months or more after complete re-
gression, following completion of the treatment. 
The observation period in all cases was at least 12 
months. After histopathological verifi cation of re-
currence, each patient underwent a series of oth-
er tests. These tests included: an ENT check-up, 
computerized tomography, a chest x-ray, an en-
doscopic examination, and an ultrasound scan of 
the abdominal cavity and neck. The patients were 
classifi ed as suitable for brachytherapy provided 
that they met the following conditions: the tumour 
had to be restricted to the upper larynx and must 
have measured 15 millimetres or less, there must 
have been no metastases to the lymph glands, nor 
should any remote metastases have been observed, 
local recurrence must have been histopathological-
ly verifi ed at least 6 months after total regression 
of a tumour following teleradiotherapy treatment. 
Having locally anaesthetized the mucous mem-
brane, a Rotterdam applicator was introduced 
into the nasopharynx. Radiological images were 
made in the antero-posterior and lateral planes 
(Figures 1,2). These images constituted the ba-
sis for calculating doses for both the tumour and 
for the healthy tissues (Figure 3). Tumour dose 
was calculated at the so called “nasopharyngeal 
point” (Na), which is situated at the intersection 
of a line joining the soft palate reference point 
and the point of the skull base bone. The distance 
between the Na point and the axis ranged from 
0.75 to 1 cm depending on the position of the ap-
plicator, which, in turn, depended on individual 
patients’ anatomy. In case of a suboptimal layout 
of doses throughout the reference points, opti-
misation took place. After a plan had been com-
pleted and accepted by a doctor, catheters were 
introduced into an applicator (R/Silisonide aer-
osol was used to facilitate their introduction) and 
then connected, by means of transferring cables, 
to the MicroSelectron HDR apparatus produced 
by Nucletron (Ir 192) (Figure 4). The patient re-
mained in contact with the doctor carrying out 
the treatment (being able to hear and see the 
doctor) throughout the procedure, which usu-
ally did not exceed a few minutes. The applica-
tor was removed from the nasopharynx following 
the completion of the whole course of treatment. 
Whenever necessary, analgesic substances, ster-
oids and irrigation were used in order to improve 
treatment tolerance.
Irradiation involved total doses of 36 Gy, i.e. 6 Gy 
applied weekly, (until 1999, in 18/28 (64.3%) of 
the patients) and 51 Gy, i.e. 3 Gy, applied twice 
daily, (after 1999 in 10/28 (35.7%) of the pa-
tients).
A normalized total dose (NTD2) was calculated 
by means of the following formula: 
NTD2=Dtotal*(df+aá/b)/(2+a/b),
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Gender
   Male  17 (60.7%)
   Female  11 (39.3%)
Age
   Average 18–73 [57,9]
   Male  59.9
   Female  54.4
Histology
   Lymphoepithelioma  20 (71.4%)
   Other  8 (28.6%)
Pre-treatment T-stage
   T1  0
   T2  9 (32.1%)
   T3  9 (32.1%)
   T4  6 (21.4%)
   Tx  4 (14.4%)
Pre-treatment N-stage
   N0  9 (32.1%)
   N1  11 (39.3%)
   N2  7 (25%)
   N3  1 (3.6%)
Total dose received (external beam radiotherapy)
   Average 66–74
Table 1. Clinical characteristics of patients with recurrence of 
nasopharyngeal cancer.
Figure 1. Radiological demonstration of a Rotterdam applicator 
– A-P projection.
Figure 2. Radiological demonstration of a Rotterdam applicator 
– lateral projection.
where:
Dtotal – total dose
D – fractionated dose
The value of a/b 10 Gy was accepted.
Statistical analysis was carried out by means of 
the program Statistica for Windows and using the 
Kaplan-Meier method, the log rank test, a multifac-
tor Cox analysis and logistic regression models.
RESULTS
Evaluation of treatment response was carried out 
on the basis of ENT, endoscopic examinations 
and, in some cases, by means of computerized 
tomography. 6 weeks after treatment completion, 
CR, PR and NC responses were noted in 64.5% 
(18/28), 32% (9/28) and 3.5% (1/28) of cases re-
spectively. The median overall failure-free survival 
period for the whole group was 76 months. The 
probabilities of surviving 3 or 5 years were 67% 
and 60% respectively (Figure 5). Nevertheless, 
an analysis of median overall failure-free survival 
time within the group of patients diagnosed with 
poorly differentiated nasopharyngeal carcinoma 
(WHO 3) showed 3 and 5 year survival rates of 
60% and 55% respectively, and among other pa-
tients 80% and 70% respectively. No statistically 
signifi cant differences in survival rates were not-
ed for the compared groups (72 vs. 77 months, 
log rank test p=0.98) (Figure 6).
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Figure 3. Isodose distribution generated from HDR brachytherapy in patients with recurrence of nasopharyngeal cancer.
Figure 4. A patient during a course of brachytherapy.
Figure 5. Overall survival time in patients after secondary 
radiotherapy.
Figure 6. A comparison of overall survival time with histopathological 
diagnosis (p=0.98).
Figure 7. Overall recurrence free survival time after secondary 
radiotherapy.
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Median overall recurrence-free survival time was 
26 months for the whole group. The probabili-
ties for 3 and 5 year recurrence-free survival rates 
for the whole group were 50% and 25% respec-
tively (Figure 7).
The survival rates for 3 and 5 recurrence-free 
years within the group of patients diagnosed 
with poorly differentiated nasopharyngeal car-
cinoma (WHO 3) were 48% and 24% respec-
tively, while within the group of patients with 
other histopathological diagnoses, the surviv-
al rate for 3 years was 55%. An analysis of me-
dian recurrence-free survival times, depending 
on histopathological diagnosis, showed no dif-
ferences between groups (log rank test p=0,88) 
(Figure 8). A multi factor Cox analysis showed 
age, T feature, total dose applied during telera-
diotherapy and total dose applied during brach-
ytherapy to be statistically signifi cant infl uences 
on overall survival time. However, these factors 
were not considered to infl uence recurrence-
free time. According to the Cox analysis, the 
only factor signifi cantly infl uencing the time 
span for local recurrence-free survival was the 
time elapsed before local recurrence actually 
developed (Tables 2,3).
The higher the normalized total dose, applied by 
means of brachytherapy, the larger the increase 
in chances for local recovery (Figure 9).
During and immediately after treatment, all pa-
tients developed acute radiation induced reac-
tions in the form of infl amed mucous membranes 
of the upper larynx. No patients developed re-
tarded radiation induced complications. No data 
was recorded in this respect in the cases of 15 
patients.
DISCUSSION
18–24% of patients with nasopharyngeal carci-
noma develop local recurrences despite increas-
ingly advanced technology in treatment meth-
ods [4,11]. Academic literature lacks universally 
accepted rules for the defi nition of local recur-
rence and for calculating the time available for 
Figure 8. A comparison of recurrence-free survival time with 
histopathological diagnosis (p=0.88).
Figure 9. The risk failure, relative to biological dose.
Factor p
Age 0.03
Pre-treatment T-stage 0.01
Total dose received
(external beam radiotherapy) 0.03
Total dose received (brachytherapy) 0.4
Table 2. The infl uence of selected factors on overall survival time 
in patients with recurrence of nasopharyngeal cancer: multivariate 
Cox analysis.
Factor p
Pre-treatment T-stage 0.1
Pre-treatment N-stage 0.9
Total dose received (brachytherapy) 0.3
Fractional dose received (brachytherapy) 0.3
Total dose received
(external beam radiotherapy) 0.8
Time to progression 0.01
Table 3. The infl uence of selected factors on overall recurrence free 
survival time in patients with nasopharyngeal cancer: multivariate 
Cox analysis.
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the implementation of salvage treatment. Most 
authors defi ne local recurrence based on the time 
in which it is developed, which ranges from 3 
to 4–6 months from the fi rst teleradiotherapy 
[12–15]. Some authors defi ne recurrence as a tu-
mour shoot following complete regression and 
disregard the time of its occurrence, while oth-
ers fail to give any explicit defi nition of recur-
rence [5,16,17]. Throughout this paper, a cut-off 
period of 6 months is assumed to allow local re-
currence to be set apart from tumours that have 
not been successfully treated. Division into early 
and late recurrences is clear-cut. Late recurrenc-
es are normally defi ned as being those that devel-
op at least 2 years after the fi rst radiotherapy and 
in such cases it is easier to make a decision as to 
whether or not to implement salvage treatment 
than in cases of early recurrence [5,18].
It is diffi cult to classify a patient with recurrent na-
sopharyngeal carcinoma, who has just undergone 
radical teleradiotherapy, with regard to proper 
treatment. According to most publications re-ir-
radiation allows attainment of 5 year survivals in 
20–40% of all cases, while treatment employing 
external radiation beams, even when treating rel-
atively small tumours (T1-2) may result in severe 
late complications [15,19]. Poor results from tel-
eradiotherapy and high mortality rates in surgi-
cal treatment make brachytherapy appear to be 
a good alternative, especially for patients with 
early advanced local recurrence (rT1, rT2), as 
is the case in about 35% of all patients develop-
ing recurrence.
Our centre used re-irradiation by means of in-
dependent brachytherapy in the cases of 28 pa-
tients with recurrent nasopharyngeal carcinoma. 
The academic literature features papers analys-
ing extremely varied groups of patients. Analyses 
included both patients with recurrent upper lar-
ynx carcinoma, at different developmental stag-
es, and patients with local treatment failures. 
The groups were often merged in analyses. It 
must be categorically stated that, as a basic con-
dition, no patients with remote metastases were 
accepted for re-irradiation. Table 4 includes ex-
amples of total doses and patient groups that un-
derwent analysis.
Our centre uses an Irydium192 source, an HDR 
afterloading technique, and total doses ranging 
from 36 to 51 Gy to irradiate patients with re-
current nasopharyngeal carcinoma. Other au-
thors have described using similar techniques 
and doses [16,20].
Syed and co-workers presented an interesting 
combination of intratissue and intracavitary 
techniques in treating patients, including those 
with recurrent nasopharyngeal carcinoma. They 
employed a manual afterloading technique and 
Ir sources whose average activities were 84 mCi. 
Doses averaged 46.7 Gy and the treatment time 
span was 105.9 hours [22].
Similar techniques and doses have been used to 
patients with recurring nasopharyngeal carcino-
ma in Japan (total doses 50–58 Gy, manual after-
loading, intratissue and intracavitary technique, 
Ir and Au sources) [12,23].
Lee et al. analysed treatment results within a 
group of 576 patients with nasopharyngeal car-
cinoma treated between 1995 and 2000. The 
patients underwent brachytherapy so as to in-
crease the doses following teleradiotherapy, both 
in treating the primary tumours and the recur-
rences. 55 patients from this group underwent 
brachytherapy as treatment for both the prima-
ry and the recurrence. Numerous applicators 
were used, including Rotterdam, balloon, and 
ovoid types and there were various strong doses 
– LDR, HDR, and PDR. Within the group of pa-
tients with recurrent nasopharyngeal carcinoma, 
64.5% of patients enjoyed total tumour regres-
sion, while 32% enjoyed partial regression. On 
the basis of their analysis, the authors concluded 
that increasing brachytherapy dose is an effective 
and well-tolerated method for the treatment of 
both primary tumours and recurrent nasopha-
ryngeal tumours [24].
Law et al. presented a paper describing the mould 
technique and irradiation by means of iridium 
rods used only in cases of patients with recur-
rent nasopharyngeal carcinoma. Total regression 
was noted in 97% of all cases while 5-year local-
ly successful treatments, recurrence free surviv-
al rates and average survival rates amounted to 
85%, 68.3% and 61.3% respectively [23].
Sham et al. reported lower locally successful treat-
ment rates (28%), having treated 30 patients with 
recurrent and persistent nasopharyngeal tumours 
by means of intracavitary techniques using caesi-
um sources and intratissue techniques employ-
ing gold sources [25].
Kwong et al. reported brachytherapy to be an 
effective salvage treatment in cases of selected 
groups of patients with either primary or re-
current carcinoma restricted to the nasal por-
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tion of the larynx. Making use of gold sources 
and the intratissue technique, the authors ana-
lysed 3 groups of patients and obtained the fol-
lowing 5 year locally successful treatment rates: 
87% within a group with persistent tumours, 62% 
within a group with a fi rst local recurrence and 
23% within a group with a second local recur-
rence (p.=0.0004). Average 5-year survivals with-
in those groups were 79.1%, 60.1% and 42.9% 
(p.=0.0047) respectively [21].
Overall 5-year survival rates for the group treat-
ed in our centre was 60%, which was similar to 
results reported by other authors [20,23].
Fisher and Partners report lower overall 5-year 
survival rate (46%) within their group of 13 pa-
tients [26].
Our own research allowed us to estimate the prob-
ability of a 5-year disease-free survival at 25%.
Syed and Partners reported higher local recurrence-
free survival rates (59%) within the group of pa-
tients with recurrent and unsuccessfully treated na-
sopharyngeal carcinoma [22]. Within the group 
that we treated the there were no differences be-
tween the probability of the overall survival time 
and the probability of recurrence-free survival time 
as far as the two groups with different histopatho-
logical check-up results were concerned. No similar 
analysis has been found in academic literature.
Leung and Partners show irradiation results with-
in the group of 87 patients with unsuccessful-
ly treated nasopharyngeal carcinoma, who, irre-
spectively of the tumour range, were treated by 
means of the HDR afterloading technique em-
ploying Co60 or Ir192 sources (total doses ranged 
from 22.5 to 25 Gy within 3 week following tel-
eradioteraphy). Treatment results in case of 
those patients were compared with results with-
in the group of 3393 patients undergoing tel-
eradiotheraphy. 5-year recurrence-free survival 
rates within these groups were respectively 85% 
and 76.6% [17].
The multifactor Cox analysis proved materials we 
have researched to include statistically signifi cant 
infl uences on the overall survival time: age, T fea-
tures, total dose applied during teleradiothera-
py and total dose applied during brachytherapy. 
Study Treatment Number of patients
Recurrence
T-stage 
5-years regional 
control (%)
5-years free 
survival from 
recurrence
(%)
5-years survival 
(%)
Complications 
(category, 
frequency)
Pryzant [19] EBR+BTHBTH 53 1–2 35 18 21
CNS complications 
– 15%
Theo [28] BTH 24 Gy/3 fr 71 1–4 69 58 – The gentle tissue necrosis – 7%
Zhang [29] EBR (45–65 Gy) + BTH (20–50 Gy 29 1–2 – –
55.5
(after 4 years) Trismus – 100%
Wang [30] EBR (40–66 Gy) + BTH (20 Gy) 51 1–4 – –
T1-2 – 38
T3-4 – 15 –
Yang [31] EBR ( 50 Gy) + BTH + CHTH 77 – – –
17–36
(after 2 years) –
Leung [16] EBR (44 Gy + BRTH (24–36 Gy) 61 – 45–82% (3 years) –
62–82
(after 3 years) Trismus – 18%
Lee [32] EBR (40–57 Gy + BRTH (10–20 Gy) 706 1–4 23 – 14 –
Choy [33] BTH 43 – 44–81 – 25–65 Tissue necrosis-fi stula 16% 
Syed [22] BTH 50–58 Gy 41 1–4 59 41 30
Tissue necrosis, 
dysphagia, 
11–14%
Table 4. Results of radiotherapy in patients with recurrence of nasopharyngeal cancer.
EBR – External Beam Radiotherapy; BTH – brachytherapy; CHTH – chemotherapy.
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Neither of these factors has been noted to infl u-
ence recurrence-free survival time. According to 
the multifactor Cox analysis, the only signifi cant 
infl uence on recurrence-free survival time, was 
the time elapsed to developing a local recurrence. 
Age infl uence on the average survival time and 
the disease-free survival time shown in the mul-
tifactor Cox analysis has been confi rmed by pa-
pers of other authors [17,21,22].
The paper presented by Syed and Partners 
analyses infl uences of sex, age, tumour range 
and lymph gland state on disease-free surviv-
al time. Probabilities of 2-, 5-, and 10- year sur-
vivals reached respectively 48%, 30% and 20%, 
while 2-, 5-, and 10- locally successful treatment 
reached respectively 81%, 59%, 49%, and 2-, 5-, 
10- year disease-free survival time was respective-
ly 56% 41% 34% [22].
Leung and Partners state that T feature was the 
only factor in the Cox analysis found to be signif-
icant for assessing infl uences that different pa-
rameters exert on chances of locally successful 
treatment. Other parameters, such as age, sex, 
persistent tumours or use of brachytherapy had 
no infl uence on treatment results. The authors 
concluded that persistent nasopharyngeal car-
cinoma may be successfully treated by means of 
brachytherapy and that patients within the ear-
ly stages of carcinoma development enjoy better 
results. Their analysis proved the T feature to be 
a more signifi cant factor than obtaining a clini-
cal remission after teleradiotherapy [17]. A mul-
tifactor analysis, presented in a paper by Kwung 
and co-workers, states that the reason for classi-
fying a patient into a certain type of treatment 
group (based on persistent disease, fi rst or sec-
ond recurrence) was the only factor signifi cant-
ly infl uencing survival rates [12].
Chua et al. observed 34 patients with recurrent na-
sopharyngeal carcinoma who were diagnosed by 
computerized tomography and treated with brach-
ytherapy. Their observations showed that patients 
with shorter recurrence-free time spans enjoyed 
longer survivals than those with longer disease-
free periods. As the authors explain, this effect was 
caused by the fact that patients with early recur-
rence often have relatively small tumour volumes 
in comparison to cases of late recurrence [14].
Early post radiation reactions of low intensi-
ty occurred in all cases in the group we treat-
ed. Other authors have reported similar data 
[16,22,25,27,28].
Late complications resulting from re-irradiat-
ing patients with nasopharyngeal carcinoma in-
clude: soft palate necrosis, temporal lobe necrosis 
(12%), deteriorated eyesight (9%), deteriorat-
ed hearing (13%), jaw clenching (30%) and en-
docrine disorders (10%). These complications 
occurred more frequently in patients whose 
treatment combined brachytherapy with telera-
diotherapy, in order to cure local recurrences 
[22,27,29–32].
Our material featured no late complications. 
However, it must be noted that some of the patients 
did not undergo any detailed observation in this re-
spect and late complications might still ensue.
CONCLUSIONS
1. HDR intracavitary brachytherapy is an effective 
treatment method in cases of patients with re-
current nasopharyngeal carcinoma.
2. The period elapsed before development of lo-
cal recurrence is a signifi cant factor infl uenc-
ing disease-free survival times.
3. The chances for successful local treatment 
among patients with nasopharyngeal carcino-
ma improves with increased total dose applied 
during brachytherapy.
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